Minh Tam Truong, MBBS, MBA
Professor, Radiation Oncology
Biography
Dr. Truong is the Chair and Professor of Radiation Oncology at Boston University Chobanian and Avedisian School of Medicine, and Chief of Radiation Oncology at Boston Medical Center.
She received her medical degree from the University of New South Wales, Sydney Australia and completed her residency in Radiation Oncology at New York University Medical Center, her last year as chief resident. She is board certified in Radiation Oncology by the American Board of Radiology. She also holds a Master’s of Business Administration from Boston University’s Questrom School of Business.
She is an internationally recognized expert in the treatment of head and neck, skin and central nervous system malignancies, as well as benign diseases, including post operative radiation for the prevention of Keloids, Airway Amyloidosis, Graves Orbitopathy.
Dr. Truong serves on a several national committees with leadership roles within the American Society for Therapeutic Radiation Oncology (ASTRO), the American Board of Radiology (ABR), and NRG Oncology (National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG)).
She is the Quality of Life Co-Chair on several international head and neck cancer multicenter trials conducted by the NRG Oncology group and has been instrumental in the prospective trial design of the Quality of Life and Patient Reported Outcome sub-studies on these trials.
She also contributes her radiation expertise to the National Cancer Institute’s Adult Oncology Treatment editorial board for over 15 years.
At Boston Medical Center, she maintains a busy clinical practice and supports many research activities at Boston Medical Center and Boston University. Over the past two decades, she has taught and mentored many Boston University Medical Students, over 80 physician residents in the Harvard Radiation Oncology Program, and Boston University physician faculty. She is actively involved in promoting clinical research activities at Boston Medical Center and was awarded funding as Principal Investigator for an American Cancer Society/Boston University Institutional Grant for the investigation of novel function imaging in head and neck cancer using CT perfusion Imaging in Patients with Head and Neck Cancer undergoing Conformal Radiotherapy. Dr. Truong has also contributed to several Boston Medical Center funded research efforts including two U.S. Army Medical Research and Material Command Office Center of Excellence Program Projects and was a project principal investigator of a department of defense funded study investigating the role of stereotactic body radiotherapy for recurrent head and neck cancer.
Her research has resulted in over 100 peer-reviewed scientific publications, editorials, book chapters, and invited reviews.
In 2022, Dr Truong was awarded the Fellow of the American Society of Radiation Oncology for her contributions to the field of Radiation Oncology and service to ASTRO.
Since 2017 to 2024, she has been named Top Doctor in Castle Connolly’s America’s Top Doctors, Exceptional Women in Medicine, and Boston Magazine.
Other Positions
- Chair, Radiation Oncology, Boston University Chobanian & Avedisian School of Medicine
- Member, BU-BMC Cancer Center, Boston University
- Member, Amyloidosis Center, Boston University
- Chief, Radiation Oncology, Boston Medical Center
- VA Boston Healthcare System
Education
- University of New South Wales, MBBS
- University of New South Wales, BSc
Publications
- Published on 3/17/2025
Paes T, Buelvas Mebarak J, Magnotto JC, Stamatiades GA, Kuang Y, Paweletz CP, Laws ER, Grosek N, Carroll RS, Jeselsohn R, Mohan DR, Marcondes Lerario A, Truong MT, Bi WL, Reardon DA, Meredith DM, Kaiser UB, Abreu AP. Somatic Activating ESR1 Mutation in an Aggressive Prolactinoma. J Clin Endocrinol Metab. 2025 Mar 17; 110(4):1166-1176. PMID: 39238355.
Read at: PubMed - Published on 11/14/2024
Mell LK, Torres-Saavedra PA, Wong SJ, Kish JA, Chang SS, Jordan RC, Liu T, Truong MT, Winquist EW, Takiar V, Wise-Draper T, Robbins JR, Rodriguez CP, Awan MJ, Beadle BM, Henson C, Narayan S, Spencer SA, Powell S, Dunlap N, Sacco AG, Hu KS, Park HS, Bauman JE, Harris J, Yom SS, Le QT. Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial. Lancet Oncol. 2024 Dec; 25(12):1576-1588. PMID: 39551064.
Read at: PubMed - Published on 9/6/2024
Lin Y, Qureshi MM, Batra S, Truong MT, Mak KS. Consecutive Daily Versus Every Other Day Stereotactic Body Radiation Therapy Scheduling for Stage I Non-small Cell Lung Cancer. Adv Radiat Oncol. 2024 Dec; 9(12):101625. PMID: 39524524.
Read at: PubMed - Published on 6/8/2023
Qureshi MM, Lin Y, Moeller AR, Yan SX, Dyer MA, Suzuki K, Everett P, Litle V, Truong MT, Mak KS. Change in stage after neoadjuvant chemoradiation is associated with survival in patients with esophageal cancer. J Surg Oncol. 2023 Oct; 128(5):781-789. PMID: 37288789.
Read at: PubMed - Published on 3/15/2023
Huang D, Qureshi MM, Truong MT, Hirsch AE. Correlation Between Research Productivity During Medical School and Radiation Oncology Residency. Adv Radiat Oncol. 2023; 8(4):101219. PMID: 37124315.
Read at: PubMed - Published on 2/10/2023
Qureshi MM, Kam A, Suzuki K, Litle V, Tapan U, Balasubramaniyan R, Dyer MA, Truong MT, Mak KS. Association between hospital safety-net burden and receipt of trimodality therapy and survival for patients with esophageal cancer. Surgery. 2023 May; 173(5):1153-1161. PMID: 36774317.
Read at: PubMed - Published on 2/8/2023
Oladeru OT, Lam CM, Qureshi MM, Hirsch AE, Mak KS, Dyer MA, Truong MT. Inequalities in Cancer Stage at Diagnosis Among Incarcerated Individuals Undergoing Radiation Therapy at a Large Safety-Net Hospital. Int J Radiat Oncol Biol Phys. 2023 May 01; 116(1):194-198. PMID: 36758643.
Read at: PubMed - Published on 12/13/2022
Dang RR, Kim J, Qureshi MM, Fazeli SR, Zhao Q, Noonan VL, Sundararajan D, Salama A, Truong MT. Impact of depth of invasion on local recurrence in R0 resected node-negative oral tongue squamous cell carcinoma. Head Neck. 2023 Mar; 45(3):561-566. PMID: 36513522.
Read at: PubMed - Published on 10/11/2022
Gillison ML, Ferris RL, Harris J, Colevas AD, Mell LK, Kong C, Jordan RC, Moore KL, Truong MT, Kirsch C, Chakravarti A, Blakaj DM, Clump DA, Ohr JP, Deeken JF, Gensheimer MF, Saba NF, Dorth JA, Rosenthal DI, Leidner RS, Kimple RJ, Machtay M, Curran WJ, Torres-Saavedra P, Le QT. Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504. Int J Radiat Oncol Biol Phys. 2023 Mar 15; 115(4):847-860. PMID: 36228746.
Read at: PubMed - Published on 9/2/2022
Subramaniam RM, DeMora L, Yao M, Yom SS, Gillison M, Caudell JJ, Waldron J, Xia P, Chung CH, Truong MT, Echevarria M, Chan JW, Geiger JL, Mell L, Seaward S, Thorstad WL, Beitler JJ, Sultanem K, Blakaj D, Le QT. 18F-FDG PET/CT Prediction of Treatment Outcomes in Human Papillomavirus-Positive, Locally Advanced Oropharyngeal Cancer Patients Receiving Deintensified Therapy: Results from NRG-HN002. J Nucl Med. 2023 Mar; 64(3):362-367. PMID: 36215572.
Read at: PubMed
View 93 more publications: View full profile at BUMC